MARKET

VKTX

VKTX

Viking Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.09
-0.12
-1.66%
Pre Market: 7.09 0 0.00% 09:06 07/02 EDT
OPEN
7.16
PREV CLOSE
7.21
HIGH
7.29
LOW
6.99
VOLUME
7
TURNOVER
--
52 WEEK HIGH
8.87
52 WEEK LOW
3.260
MARKET CAP
514.71M
P/E (TTM)
-16.7454
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VKTX stock price target is 19.38 with a high estimate of 40.00 and a low estimate of 12.00.

EPS

VKTX News

More
Edited Transcript of VKTX earnings conference call or presentation 30-Apr-20 8:30pm GMT
Thomson Reuters StreetEvents · 2d ago
Should You Buy Viking Therapeutics, Inc. (VKTX)?
Insider Monkey · 06/24 18:07
Many 'Ifs' Surrounding Viking Therapeutics
GuruFocus.com · 06/15 22:19
New kid on the block in race for NASH drug
Seeking Alpha - Article · 06/15 21:34
Why Viking Therapeutics Is Trading Higher Today
Benzinga · 06/05 16:17
Why Viking Therapeutics Is Trading Higher Today
Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher on Friday. BMO Capital initiated coverage on the stock with an Outperform rating and a price target of $14 per share.
Benzinga · 06/05 15:17
Benzinga's Top Upgrades, Downgrades For June 5, 2020
Benzinga · 06/05 14:56
BMO Capital Initiates Coverage On Viking Therapeutics with Outperform Rating, Announces Price Target of $14
BMO Capital analyst Matthew Luchini initiates coverage on Viking Therapeutics (NASDAQ:VKTX) with a Outperform rating and announces Price Target of $14.
Benzinga · 06/05 10:24

Industry

Biotechnology & Medical Research
-0.32%
Pharmaceuticals & Medical Research
+0.19%

Hot Stocks

Symbol
Price
%Change

About VKTX

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.
More

Webull offers kinds of Viking Therapeutics Inc stock information, including NASDAQ:VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.